Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

S Bringhen, M Offidani, S Palmieri, F Pisani, R Rizzi, S Spada, A Evangelista, N Di Renzo, P Musto, M Marcatti, R Vallone, S Storti, A Bernardini, R Centurioni, E Aitini, A Palmas, O Annibali, E Angelucci, P Ferrando, A BaraldiS Rocco, A Andriani, A Siniscalchi, V De Stefano, V Meneghini, A Palumbo, S Grammatico, M Boccadoro, A Larocca

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients
Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume130
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis'. Together they form a unique fingerprint.

Cite this